IMRN
Immuron Limited
Price Chart
Latest Quote
$1.11
+0.03 (+2.78%)
Current Price
| Previous Close | $1.08 |
| Open | $1.05 |
| Day High | $1.17 |
| Day Low | $1.01 |
| Volume | 7,614 |
Stock Information
Note: Financial values converted from AUD to USD
| Shares Outstanding | 8.07M |
| Total Debt | $141K |
| Cash Equivalents | $6.90M |
| Revenue | $5.16M |
| Net Income | $-3.21M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $8.96M |
| EPS (TTM) | $-0.52 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-972K |
| Sales | $5.16M |
| Income | $-3.21M |
| Book/sh | $1.12 |
| Cash/sh | $1.24 |
| Employees | 7 |
Financial Ratios
| Quick Ratio | 6.75 |
| Current Ratio | 8.04 |
| Debt/Eq | 1.56 |
Returns & Margins
| ROA | -21.93% |
| ROE | -39.68% |
| Gross Margin | 63.69% |
| Operating Margin | -47.16% |
| Profit Margin | -62.14% |
Ownership
| Institutional Ownership | 1.04% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -111.00 |
| P/S | 1.20 |
| P/B | 0.99 |
Analyst Data
| Recommendation | none |
| Target Price | $3.86 |
Technical Indicators
| SMA20 | $1.21 |
| SMA50 | $1.03 |
| SMA200 | $1.22 |
| RSI | 35.19 |
| ATR | 0.1188 |
| Shares Float | 7.99M |
| Short Float | 10.18% |
| Short Ratio | 0.90 |
| Volatility | 0.49 |
| Rel Volume | 0.04 |
Performance History
| Week | +3.74% |
| Month | +9.90% |
| Quarter | +44.16% |
| 6 Months | +17.71% |
| YTD | +39.62% |
| Year | -40.32% |
| 3 Years | -43.08% |
| 5 Years | -77.11% |
| 10 Years | -86.71% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $1.11 | 7,614 |
| 2026-06-24 | $1.08 | 93,000 |
| 2026-06-23 | $1.11 | 23,900 |
| 2026-06-22 | $1.15 | 77,600 |
| 2026-06-18 | $1.06 | 8,600 |
| 2026-06-17 | $1.07 | 38,700 |
| 2026-06-16 | $1.12 | 23,600 |
| 2026-06-15 | $1.16 | 45,500 |
| 2026-06-12 | $1.19 | 24,800 |
| 2026-06-11 | $1.24 | 28,500 |
| 2026-06-10 | $1.17 | 97,800 |
| 2026-06-09 | $1.19 | 26,400 |
| 2026-06-08 | $1.20 | 49,600 |
| 2026-06-05 | $1.25 | 34,400 |
| 2026-06-04 | $1.27 | 72,600 |
| 2026-06-03 | $1.37 | 102,300 |
| 2026-06-02 | $1.32 | 147,500 |
| 2026-06-01 | $1.41 | 255,500 |
| 2026-05-29 | $1.45 | 570,900 |
| 2026-05-28 | $1.21 | 2,099,400 |
| 2026-05-27 | $1.22 | 9,631,100 |
| 2026-05-26 | $1.01 | 24,900 |
About Immuron Limited
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. In additon, the company develops IMM-986, that is in pre-clinical stage. Further, it offers technology platform. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
đ° Latest News
Immuron (IMRN) Struggles After Announcing Trial Results
Insider Monkey âĸ 2025-12-15T17:36:05Z
Immuron (IMRN) Posts 49% FY2025 Revenue Growth on Travelan Sales
Insider Monkey âĸ 2025-09-30T19:05:41Z
Immuron Full Year 2025 Earnings: AU$0.023 loss per share (vs AU$0.03 loss in FY 2024)
Simply Wall St. âĸ 2025-08-31T23:32:51Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $1,769,632 | $1,098,918 | $347,736 | $169,596 |
| Cost Of Revenue | $1,769,632 | $1,098,918 | $347,736 | $169,596 |
| Total Revenue | $5,113,327 | $3,440,366 | $1,266,371 | $536,940 |
| Operating Revenue | $5,113,327 | $3,440,366 | $1,266,371 | $536,940 |
| Expenses | ||||
| Interest Expense | $5,126 | $5,316 | $6,773 | $4,339 |
| Total Expenses | $8,872,173 | $7,100,347 | $3,656,743 | $2,724,445 |
| Other Income Expense | $8,549 | $-1,432,389 | $-341,490 | $173,713 |
| Net Non Operating Interest Income Expense | $90,212 | $224,672 | $74,852 | $10,947 |
| Interest Expense Non Operating | $5,126 | $5,316 | $6,773 | $4,339 |
| Operating Expense | $7,102,540 | $6,001,429 | $3,309,008 | $2,554,849 |
| Other Operating Expenses | $-990,460 | $-2,391,551 | $-2,120,855 | $-672,041 |
| Selling And Marketing Expense | $2,422,578 | $1,424,214 | $650,778 | $292,286 |
| General And Administrative Expense | $3,097,819 | $3,172,712 | $2,912,607 | $2,437,003 |
| Rent Expense Supplemental | - | $16,927 | - | $0 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-3,660,085 | $-4,867,699 | $-2,657,012 | $-2,002,845 |
| Net Interest Income | $90,212 | $224,672 | $74,852 | $10,947 |
| Interest Income | $95,338 | $229,988 | $81,624 | $15,287 |
| Normalized Income | $-3,668,634 | $-4,457,005 | $-2,543,112 | $-2,176,557 |
| Net Income From Continuing And Discontinued Operation | $-3,660,085 | $-4,867,699 | $-2,657,012 | $-2,002,845 |
| Total Operating Income As Reported | $-3,750,297 | $-4,070,674 | $-2,504,272 | $-2,013,792 |
| Net Income Common Stockholders | $-3,660,085 | $-4,867,699 | $-2,657,012 | $-2,002,845 |
| Net Income | $-3,660,085 | $-4,867,699 | $-2,657,012 | $-2,002,845 |
| Net Income Including Noncontrolling Interests | $-3,660,085 | $-4,867,699 | $-2,657,012 | $-2,002,845 |
| Net Income Continuous Operations | $-3,660,085 | $-4,867,699 | $-2,657,012 | $-2,002,845 |
| Pretax Income | $-3,660,085 | $-4,867,699 | $-2,657,012 | $-2,002,845 |
| Special Income Charges | $0 | $0 | $-1,667 | $0 |
| Earnings From Equity Interest | $0 | $-1,021,696 | $-227,591 | $0 |
| Interest Income Non Operating | $95,338 | $229,988 | $81,624 | $15,287 |
| Operating Income | $-3,758,846 | $-3,659,981 | $-2,390,373 | $-2,187,505 |
| Depreciation Amortization Depletion Income Statement | $34,866 | $32,265 | $34,146 | $29,897 |
| Depreciation And Amortization In Income Statement | $34,866 | $32,265 | $34,146 | $29,897 |
| Depreciation Income Statement | $34,866 | $32,265 | $34,146 | $29,897 |
| Gross Profit | $3,343,695 | $2,341,448 | $918,635 | $367,344 |
| Per Share | ||||
| Diluted EPS | $-0.64 | $-0.85 | $-0.47 | $-0.35 |
| Basic EPS | $-0.64 | $-0.85 | $-0.47 | $-0.35 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-3,628,642 | $-4,419,424 | $-2,502,193 | $-2,142,321 |
| Total Unusual Items | $8,549 | $-410,693 | $-113,899 | $173,713 |
| Total Unusual Items Excluding Goodwill | $8,549 | $-410,693 | $-113,899 | $173,713 |
| Reconciled Depreciation | $34,866 | $32,265 | $34,146 | $29,897 |
| EBITDA (Bullshit earnings) | $-3,620,093 | $-4,830,117 | $-2,616,092 | $-1,968,609 |
| EBIT | $-3,654,959 | $-4,862,382 | $-2,650,239 | $-1,998,505 |
| Diluted Average Shares | $4,059,696 | $4,003,041 | $4,001,523 | $3,992,346 |
| Basic Average Shares | $4,059,696 | - | $4,001,523 | $3,992,346 |
| Diluted NI Availto Com Stockholders | $-3,660,085 | $-4,867,699 | $-2,657,012 | $-2,002,845 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Write Off | $0 | $0 | $1,667 | $0 |
| Gain On Sale Of Security | $8,549 | $-410,693 | $-112,232 | $173,713 |
| Provision For Doubtful Accounts | $13,496 | $-8,201 | $13,410 | $6,181 |
| Research And Development | $2,524,241 | $3,771,989 | $1,818,922 | $461,522 |
| Selling General And Administration | $5,520,397 | $4,596,927 | $3,563,384 | $2,729,289 |
| Other Gand A | $1,017,379 | $1,166,751 | $1,033,332 | $1,194,017 |
| Insurance And Claims | $248,156 | $225,724 | $305,031 | $281,469 |
| Salaries And Wages | $1,832,284 | $1,780,237 | $1,574,245 | $961,517 |
| Rent And Landing Fees | - | $16,927 | - | $0 |
| Other Special Charges | - | - | - | - |
| Other Taxes | - | - | - | - |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $5,662,098 | $8,918,282 | $13,765,235 | $16,263,702 |
| Total Assets | $7,108,162 | $10,911,493 | $15,429,221 | $17,441,460 |
| Total Non Current Assets | $80,427 | $577,947 | $1,107,884 | $830,589 |
| Other Non Current Assets | $467 | $469,641 | $855,832 | $671,487 |
| Current Assets | $7,027,736 | $10,333,547 | $14,321,337 | $16,610,871 |
| Other Current Assets | $5,379 | $7,047 | - | - |
| Prepaid Assets | $2,441,287 | $60,907 | $110,975 | $401,656 |
| Inventory | $1,243,676 | $1,111,928 | $589,410 | $229,161 |
| Receivables | $1,351,199 | $973,667 | $292,906 | $465,158 |
| Other Receivables | $795,875 | $558,817 | $279,553 | $318,961 |
| Accounts Receivable | $555,323 | $414,850 | $13,353 | $146,197 |
| Allowance For Doubtful Accounts Receivable | $-24,887 | $-11,391 | $-19,592 | $-6,181 |
| Gross Accounts Receivable | $580,210 | $426,241 | $32,944 | $152,378 |
| Cash Cash Equivalents And Short Term Investments | $1,986,195 | $8,179,998 | $13,328,046 | $15,514,896 |
| Cash And Cash Equivalents | $1,986,195 | $8,179,998 | $12,041,095 | $15,514,896 |
| Cash Financial | $1,986,195 | $8,179,998 | $12,041,095 | $15,514,896 |
| Debt | ||||
| Total Debt | $50,421 | $93,285 | $132,687 | $147,209 |
| Long Term Debt And Capital Lease Obligation | $50,421 | $93,285 | $105,484 | $123,087 |
| Current Debt And Capital Lease Obligation | - | $28,458 | $27,203 | $24,122 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,446,065 | $1,993,211 | $1,663,986 | $1,177,758 |
| Total Non Current Liabilities Net Minority Interest | $66,365 | $99,324 | $106,804 | $123,112 |
| Current Liabilities | $1,379,700 | $1,893,887 | $1,557,181 | $1,054,646 |
| Other Current Liabilities | $31,768 | $28,458 | - | $24,122 |
| Payables And Accrued Expenses | $1,073,212 | $1,498,738 | $836,972 | $814,605 |
| Payables | $727,375 | $484,458 | $560,482 | $525,563 |
| Other Payable | $20,994 | $29,156 | $5,490 | $19,727 |
| Accounts Payable | $706,381 | $455,302 | $554,992 | $505,836 |
| Current Deferred Liabilities | - | $0 | $489,927 | $0 |
| Equity | ||||
| Common Stock Equity | $5,662,098 | $8,918,282 | $13,765,235 | $16,263,702 |
| Total Equity Gross Minority Interest | $5,662,098 | $8,918,282 | $13,765,235 | $16,263,702 |
| Stockholders Equity | $5,662,098 | $8,918,282 | $13,765,235 | $16,263,702 |
| Gains Losses Not Affecting Retained Earnings | $1,150,448 | $2,227,070 | $2,270,696 | $2,221,893 |
| Retained Earnings | $-57,850,822 | $-55,412,531 | $-50,561,643 | $-48,014,373 |
| Long Term Equity Investment | - | $0 | $111,617 | $0 |
| Other | ||||
| Ordinary Shares Number | $164,170,247 | $159,987,616 | $159,847,275 | $159,847,275 |
| Share Issued | $164,170,247 | $159,987,616 | $159,847,275 | $159,847,275 |
| Tangible Book Value | $5,662,098 | $8,918,282 | $13,765,235 | $16,263,702 |
| Invested Capital | $5,662,098 | $8,918,282 | $13,765,235 | $16,263,702 |
| Working Capital | $5,648,036 | $8,439,659 | $12,764,156 | $15,556,225 |
| Capital Lease Obligations | $50,421 | $93,285 | $132,687 | $147,209 |
| Total Capitalization | $5,662,098 | $8,918,282 | $13,765,235 | $16,263,702 |
| Capital Stock | $62,362,471 | $62,103,744 | $62,056,182 | $62,056,182 |
| Common Stock | $62,362,471 | $62,103,744 | $62,056,182 | $62,056,182 |
| Employee Benefits | $15,944 | $6,038 | $1,321 | $25 |
| Long Term Capital Lease Obligation | $50,421 | $93,285 | $105,484 | $123,087 |
| Pensionand Other Post Retirement Benefit Plans Current | $274,720 | $366,691 | $203,079 | $148,604 |
| Current Accrued Expenses | $345,837 | $1,014,280 | $276,490 | $289,041 |
| Net PPE | $79,959 | $108,306 | $140,434 | $159,102 |
| Other Inventories | $25 | $105,953 | $479 | $26 |
| Finished Goods | $799,979 | $428,054 | $276,739 | $45,557 |
| Work In Process | $303,874 | $479,861 | $312,192 | $87,301 |
| Raw Materials | $139,799 | $98,060 | $0 | $96,278 |
| Treasury Shares Number | - | $0 | - | - |
| Current Deferred Revenue | - | $0 | $489,927 | $0 |
| Current Capital Lease Obligation | - | $28,458 | $27,203 | $24,122 |
| Investments And Advances | - | $0 | $111,617 | $0 |
| Accumulated Depreciation | - | $-348,632 | $-316,367 | $-282,221 |
| Gross PPE | - | $456,938 | $456,802 | $441,323 |
| Leases | - | $170,761 | $170,761 | $160,712 |
| Machinery Furniture Equipment | - | $286,178 | $286,041 | $280,610 |
| Properties | - | $0 | $0 | $0 |
| Other Short Term Investments | - | $0 | $1,286,951 | $0 |
| Other Properties | - | - | $170,761 | $160,712 |
| Current Provisions | - | - | - | $67,315 |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-4,306,329 | $-4,126,261 | $-1,826,492 | $-2,215,873 |
| Operating Activities | ||||
| Cash Flowsfromusedin Operating Activities Direct | $-4,306,329 | $-4,126,124 | $-1,821,062 | $-2,208,823 |
| Classesof Cash Receiptsfrom Operating Activities | $6,059,742 | $4,933,418 | $3,681,747 | $1,039,468 |
| Other Cash Receiptsfrom Operating Activities | - | - | - | - |
| Investing Activities | ||||
| Investing Cash Flow | $-2,035,234 | $229,851 | $-1,839,365 | $8,236 |
| Cash Flow From Continuing Investing Activities | $-2,035,234 | $229,851 | $-1,839,365 | $8,236 |
| Capital Expenditure | - | $-137 | $-5,430 | $-7,051 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $278,456 | $16,841 | $0 | $0 |
| Financing Cash Flow | $140,164 | $582 | $-31,343 | $-29,786 |
| Cash Flow From Continuing Financing Activities | $140,164 | $582 | $-31,343 | $-29,786 |
| Net Other Financing Charges | $-87,091 | - | - | - |
| Cash Dividends Paid | $0 | $0 | $0 | $0 |
| Net Common Stock Issuance | $278,456 | $16,841 | $0 | $0 |
| Common Stock Issuance | $278,456 | $16,841 | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $-46,075 | $-10,943 | $-24,570 | $-25,447 |
| End Cash Position | $1,986,195 | $8,179,998 | $12,041,095 | $15,514,896 |
| Beginning Cash Position | $8,179,998 | $12,041,095 | $15,514,896 | $17,575,806 |
| Effect Of Exchange Rate Changes | $7,596 | $34,594 | $217,969 | $169,462 |
| Changes In Cash | $-6,201,399 | $-3,895,691 | $-3,691,770 | $-2,230,373 |
| Interest Paid Cff | $-5,126 | $-5,316 | $-6,773 | $-4,339 |
| Net Issuance Payments Of Debt | $-46,075 | $-10,943 | $-24,570 | $-25,447 |
| Net Long Term Debt Issuance | $-46,075 | $-10,943 | $-24,570 | $-25,447 |
| Long Term Debt Payments | $-46,075 | $-10,943 | $-24,570 | $-25,447 |
| Interest Received Cfi | $95,338 | $229,988 | $81,624 | $15,287 |
| Net Investment Purchase And Sale | $-2,130,572 | $0 | $0 | - |
| Purchase Of Investment | $-2,130,572 | $0 | $0 | - |
| Net Business Purchase And Sale | $0 | $0 | $-1,915,559 | $0 |
| Purchase Of Business | $0 | $0 | $-1,915,559 | $0 |
| Net PPE Purchase And Sale | $0 | $-137 | $-5,430 | $-7,051 |
| Purchase Of PPE | $0 | $-137 | $-5,430 | $-7,051 |
| Taxes Refund Paid Direct | $539,213 | $277,174 | $176,820 | $214,830 |
| Classesof Cash Payments | $-10,366,071 | $-9,059,542 | $-5,502,808 | $-3,248,291 |
| Paymentsto Suppliersfor Goodsand Services | $-10,366,071 | $-9,059,542 | $-5,502,808 | $-3,248,291 |
| Receiptsfrom Government Grants | $192,778 | $1,334,126 | $2,162,783 | $335,828 |
| Receiptsfrom Customers | $5,327,750 | $3,322,118 | $1,342,144 | $488,810 |
| Issuance Of Debt | - | - | $0 | $0 |
| Long Term Debt Issuance | - | - | $0 | $0 |
Fetched: 2026-06-18